Current research indicates that the use of toluidine, selective β2-AR agonists, 17β-estradiol, ciliary neurotrophic factors, and low-dose gamma radiation can regulate Cx43 expression as a potential treatment strategy for glioma [38, 59]. The gene discussed is GJA1; the disease is central nervous system cancer.